MedTrace Logo

Brain Mets - Capecitabine Plus Sunitinib and WBRT

NCT00570908 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2014-09-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy and safety of concurrent whole brain radiotherapy (WBRT) and capecitabine followed by combination capecitabine and sunitinib in treating patients with CNS metastases from breast cancer.

Conditions

Interventions

DRUG

sunitinib

Sutent

DRUG

capecitabine

concurrently

RADIATION

WBRT

Whole Brain Radiotherapy 30 Gy in 10 fractions

Sponsors & Collaborators

  • Baylor Breast Care Center

    lead OTHER

Principal Investigators

  • Mothaffar' Rimawi, MD · Baylor College of Medicine, Breast Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00570908 on ClinicalTrials.gov